Loading
A phase 2/3 trial testing SCTB41 in non-small-cell lung cancer, now recruiting.
SCTB41 Combined With Chemotherapy in Advanced Squamous Non-Small Cell Lung Cancer is a phase 2/3 interventional study registered as NCT07662395, led by Sinocelltech, and recruiting on the registry. Official title: A Multicenter Phase II/III Study Evaluating the Efficacy and Safety of SCTB41 Combined With Chemotherapy Versus Tislelizumab Combined With Chemotherapy as First-Line Treatment for Driver-Negative Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC). Planned enrolment is 410 participants (estimated). The study started in 2026-05-09 and primary completion is expected in 2030-01-24. No results have been posted on ClinicalTrials.gov.
Shares SCTB41, Sinocelltech.
Shares SCTB41, Sinocelltech, Non-small-cell lung cancer.
Shares Sinocelltech, Non-small-cell lung cancer.
Shares Sinocelltech, Non-small-cell lung cancer.